drugset / Trial / NCT03768349

PSMA and C-11 Choline PET in Patients With Biochemical Recurrence of Prostate Cancer

NCT03768349

Phase 0 Completed 250 enrolled Mayo Clinic
Non-randomizedParallel-groupOpen-labelDiagnostic

Summary

Imaging and staging of prostate cancer is critical for surgical and treatment planning. In this protocol we will image patients with suspected metastatic prostate cancer using 11C-Choline PET and Gallium-68 labeled HBED-CC PSMA (more commonly called 68Ga-PSMA-11) or F-18 labeled PSMA 1007 in order to demonstrate their utility in detecting prostate cancer.

Timeline

Start
2019-01-03
Primary completion
2021-07-21
Completion
2021-07-21

Drugs

EvaluationDrugModalityDoseRoute
Subject 68Ga-PSMA-11 Diagnostic / imaging agent
Subject F-18 PSMA 1007 Diagnostic / imaging agent

Indications